Q2 2021

Filed Aug 12, 2021 · 10-Q · 43 days after period end · 0001654954-21-008864

Q2 2021 · 10-Q

Revenue—

Net Income

-$3.20M

N/M vs Q2 2020

EPS Diluted

-$0.08

N/M vs Q2 2020

Operating Income-$3,200,190N/M

Operating Cash Flowderived-$2,799,412N/M

Same quarter

Metric	Q2 2021	Q2 2020	Q2 2019	Q2 2018
Revenue	—	—	$0.00	$0.00
Net Income	-$3.20M	-$2.89M	-$2.33M	-$1.85M
EPS Diluted	-$0.08	-$0.20	-$0.31	-$0.47

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR